Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. [electronic resource]
Producer: 20201103Description: 191-195 p. digitalISSN:- 2168-6084
- Adolescent
- Disease Progression
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Keratoderma, Palmoplantar -- drug therapy
- Male
- Mutation
- Protein Kinase Inhibitors -- administration & dosage
- Syndrome
- TRPV Cation Channels -- genetics
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.